What makes bispecific antibodies different from CAR T-cell therapy? Watch the full episode of #HematologyHighlights to learn more: https://bit.ly/45LYGIc #MultipleMyeloma #Hematology #Oncology #BispecificAntibodies

“The best cancer fighter is our own immune system.” Watch now: https://bit.ly/4wGOqgx #MultipleMyeloma #HematologyHighlights #CancerResearch

Hematology Highlights by Decera Clinical Insights, Dr. Richter discusses treatment strategies for patients with relapsed/refractory multiple myeloma who are ineligible for or decline T-cell redirection therapies, including CAR T-cell therapy and bispecific antibodies. Watch: https://bit.ly/4wGOqgx

In this episode of Hematology Unscripted by Decera Clinical Insights, Dr. Joshua Richter explores how to manage patients with multiple myeloma in the critical period leading up to CAR T-cell therapy. Watch: https://bit.ly/3Rhp8pD #MultipleMyeloma #CARTCellTherapy #HematologyUnscripted

Hematology Unscripted by Decera Clinical Insights explores the complex decisions clinicians face in treating blood cancers. Follow the series for evidence-informed conversations on multiple myeloma, CAR T-cell therapy, bispecific antibodies, sequencing strategies, and more. https://bit.ly/3Rhp8pD

As MRD ctDNA testing evolves, could it help guide more personalized treatment approaches in early breast cancer? John Marshall, MD, and Marija Balic, MD, discuss emerging data, assay sensitivity, and what may be possible in the future. Watch here: https://bit.ly/3ZDiQBg

Hematology Unscripted by Decera Clinical Insights is here. Hosted by Dr. Joshua Richter, this new series explores the complex decisions clinicians face in blood cancer care, from CAR T-cell therapy and bispecifics to sequencing and bridging strategies. Stay tuned: https://bit.ly/3Rhp8pD

In the latest episode of Oncology Unscripted, Dr. Marshall, discusses why biomarker testing is becoming an essential component of cancer care, the growing role of MRD and ctDNA testing, and emerging research that may further expand the impact of precision oncology. Watch: https://bit.ly/3ZDiQBg

MRD ctDNA testing is generating significant interest in early breast cancer care. In this episode of Oncology Unscripted, John Marshall, MD, and Marija Balic, MD, discuss the potential role of MRD testing and where the science is headed next. Watch here: https://bit.ly/4amh2md

Precision medicine is becoming a standard part of cancer care. In the latest #OncologyUnscripted episode, John Marshall, MD, discusses how ctDNA and MRD testing are shaping treatment decisions today—and the potential of blood-based cancer screening in the future. Watch: https://bit.ly/2GmLq22

Catch up on the latest episodes of Oncology Unscripted with John Marshall, MD 🎙️ Explore the expanding role of precision medicine, the impact of AI in cancer care, and key trends shaping the future of oncology. Watch 👉 https://bit.ly/3ZDiQBg #Oncology #OncologyInsights #ScientificActivation

“There’s no way around it anymore.” Precision medicine is now standard of care. #OncologyUnscripted by Decera Clinical Insights 🎧 Episode 30: https://bit.ly/3ZDiQBg #Oncology #EvidenceToAction #ScientificActivation #DecodingScience

AI is rapidly expanding its role in oncology, but it’s also raising important questions. From precision medicine to real-time health monitoring, the possibilities are expanding—but so is the need for thoughtful oversight. 🔗 Watch the full episode: https://bit.ly/3ZDiQBg

“Telepresence is not the same as presence.” In this episode of Oncology Unscripted, De John Marshall reflects on what AI can’t replace in cancer care. AI is here to stay. The question is how we preserve what makes care human. 🔗 Watch the episode: https://bit.ly/3ZDiQBg #AIinHealthcare

In this episode of Oncology Unscripted John Marshall, MD is joined by Neel Trivedi, MD; Ross Filice, MD; and Torbjørn Furuseth, MD to explore how AI is being used today and where it may be headed next. 🎉 Watch the full episode: https://bit.ly/3ZDiQBg

AI is rapidly reshaping cancer care, but where do we draw the line? In this episode of #OncologyUnscripted, Dr Marshall explores both the promise and the pressure of AI in oncology, from predicting treatment responses and supporting clinical trials and more! 🔗 Watch here: https://bit.ly/3ZDiQBg

Catch up on the latest Oncology Unscripted episodes with Dr. John Marshall 🍃 👉 https://bit.ly/3ZDiQBg #Oncology #CancerCare #GICancer #OncologyInsights

Cancer doesn’t evolve slowly anymore. As treatments advance, cancer adapts, often faster than we expect. While AI is reshaping care, they’re also raising an important question: What role does the physician play in a rapidly evolving, tech-driven future? 👉 Watch: https://bit.ly/3ZDiQBg

What does leadership in oncology look like over time? Sometimes, it’s believing in something before the field catches up. Dr. Marshall and Dr. Weiner reflect on the early days of immunotherapy and what it takes to stay committed to a vision. Watch the full discussion: https://bit.ly/3ZDiQBg

Standing in the Galápagos, it’s hard not to think about evolution, and what it means for oncology. Dr. John Marshall connects a recent cholangiocarcinoma study to the global evolution of cancer research and care. https://bit.ly/3ZDiQBg #OncologyUnscripted #CancerCare

Leadership in oncology is constantly evolving. In this conversation, Dr. John Marshall and Dr. Louis Weiner reflect on leading through change, advancing innovation, and the impact of immunotherapy. Watch the full discussion: https://bit.ly/3ZDiQBg #ClinicalInsights #Oncology

What’s happening at the FDA right now? In this #OncologyUnscripted clip, Dr. John Marshall discusses staffing cuts, leadership turnover, and structural changes, and what it could mean for cancer innovation and access to new therapies. ▶️ Watch the clip: https://bit.ly/3OIu1Xk

What happens to cancer care when instability hits the systems that support drug development and approval? Dr. Marshall discusses growing uncertainty at the FDA, from job cuts to leadership turnover and structural changes, and more! Watch: https://bit.ly/3OIu1Xk

$25 trillion. That’s the projected global cost of cancer care over the next 30 years, while many patients still lack access to basic treatment. Are we expanding access… or just escalating costs? New episode of #OncologyUnscripted: https://bit.ly/4aWDGAT

Cancer incidence is rising, breast, prostate, young-onset colon cancer, melanoma. Yet mortality has fallen >30%. Global cancer costs may reach $25T. We’re curing more patients, but funding threats put progress at risk. Watch #OncologyUnscripted: https://bit.ly/4aWDGAT

In this #OncologyUnscripted conversation, Dr John Marshall reflects on emerging data linking the microbiome to early-onset colon cancer risk and survival, including findings showing improved colon cancer mortality among patients taking GLP-1 receptor agonists. Watch: https://bit.ly/4khD0Ks

Fiber isn’t about restriction, it’s about feeding the right ecosystem 🌱 Robynne Chutkan, MD breaks down why unprocessed plant fiber fuels gut microbes, drives short-chain fatty acid production, and helps keep the immune system in balance. Watch the full episode: https://bit.ly/3Mc62yL

Why are more young adults being diagnosed with colorectal cancer? In this #OncologyUnscripted episode, John Marshall, MD digs into emerging research on bacteria-produced mutagens like colibactin and more... ✨ Watch the full conversation: https://bit.ly/4khD0Ks

How much does the gut really influence modern disease? In this #OncologyUnscripted conversation, Dr John Marshall sits down with Dr Robynne Chutkan to unpack the microbiome and more! ✨ Watch here: https://bit.ly/3Mc62yL

Catch up on the latest Oncology Unscripted episodes with John Marshall, MD 🍃 New conversations are now live! Watch the newest episodes here 👉 https://bit.ly/3M5Tady #GICancer #OncologyInsights